MPR Weekly Dose Podcast #274 — Ozempic Tablets; ALS Tx Fast Tracked; Phase 3 results for aficamten in HCM; Motion Sickness Drug Approved; Lantus Alternative

Ozempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten in non-obstructive hypertrophic cardiomyopathy; motion sickness drug Nereus now available; Lantus alternative Langlara gains approval.

Episode metadata supplied by the publisher feed · Published May 8, 2026

Embed this episode

Attribution link and audio player

Ready to play

MPR Weekly Dose Podcast #274 — Ozempic Tablets; ALS Tx Fast Tracked; Phase 3 results for aficamten in HCM; Motion Sickness Drug Approved; Lantus Alternative

0:00 9:51

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 9 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on May 8, 2026.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!